Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 4:30 p.m. ...
(Date:7/31/2014)... Fla. (PRWEB) July 31, 2014 The Kidney ... distribution of its monthly news magazine, Kidney Cancer News. ... a presence on a website maintained by an international news ... an immediate increase in viewers.” , This month’s program highlights ... kidney tumors analyzed in a recent study. Kidney Cancer ...
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SNY) today announced that the Companies intend to use ... disease priority review voucher in connection with the Biologics ... voucher entitles the holder to designate a BLA for ... from the filing date instead of the standard 10-month ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... SUNNYVALE, Calif., Oct. 29 Accuray,Incorporated (Nasdaq: ARAY ... today that it is rescheduling the earnings release call ... financial results for,the first quarter of fiscal 2009, ended ... available at this time, certain,aspects of Accuray,s quarterly reporting ...
... at ImClone Brings Substantial,Oncology Drug Development Expertise, ... ("Senesco" or the "Company") (NYSE Alternext US: SNT),announced ... 55 to its board,of directors. Senesco,s board of ... are independent., (Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 ), ...
... Medical,Innovations, Inc. (Amex: IMA ), a global leader ... for the quarter,ended September 30, 2008., In the ... of,$438.8 million compared to net revenue of $237.6 million ... primarily due to $118.7 million,of incremental revenue provided by ...
Cached Biology Technology:Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009 2Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009 3Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009 4Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 2Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 3Inverness Medical Innovations Announces Third Quarter 2008 Results 2Inverness Medical Innovations Announces Third Quarter 2008 Results 3Inverness Medical Innovations Announces Third Quarter 2008 Results 4Inverness Medical Innovations Announces Third Quarter 2008 Results 5Inverness Medical Innovations Announces Third Quarter 2008 Results 6Inverness Medical Innovations Announces Third Quarter 2008 Results 7Inverness Medical Innovations Announces Third Quarter 2008 Results 8Inverness Medical Innovations Announces Third Quarter 2008 Results 9Inverness Medical Innovations Announces Third Quarter 2008 Results 10Inverness Medical Innovations Announces Third Quarter 2008 Results 11Inverness Medical Innovations Announces Third Quarter 2008 Results 12Inverness Medical Innovations Announces Third Quarter 2008 Results 13Inverness Medical Innovations Announces Third Quarter 2008 Results 14Inverness Medical Innovations Announces Third Quarter 2008 Results 15Inverness Medical Innovations Announces Third Quarter 2008 Results 16
(Date:7/30/2014)... between two points is a straight line, and now ... the familiar axiom to heart. , Though competition ... with each racing for the chance to fertilize the ... cooperative groups that allow them to take a straighter ... conducted by Heidi Fisher, a post-doctoral student working in ...
(Date:7/30/2014)... female baboons suggests that the route to a higher rank ... lots of supportive sisters. , A female baboon,s social status ... rank of her mother - the higher the mother is ... dominance rank in female baboons is thought to be determined ... good spot in the pecking order, whereas females born to ...
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3NexID Biometrics Joins the FIDO Alliance 2
... found one of the bodys own neurotransmitters released during ... brain that increases production of a protein that could ... may explain why approximately 30 percent of patients with ... study, conducted by researchers at the National Institute of ...
... people are to be analysed in a 30 million follow ... the largest ever study of the genetics behind common diseases. ... analysed will allow researchers to look at a 25 diseases ... and individuals, responses to statins. Funded by the Wellcome ...
... vitamins and minerals in the diet can stimulate or ... will present their findings on biological markers that could ... American Association for Cancer Research meeting in San Diego. ... diet with calcium and vitamin D appeared to increase ...
Cached Biology News:Brain study may lead to improved epilepsy treatments 2Largest ever study of genetics of common disease just got bigger 2Vitamin D and calcium influence cell death in the colon, researchers find 2
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: